Intracerebroventricular administration of somatostatin prevents and attenuates adjuvant arthritis

Simple item page
dc.FacultyEndemic Diseasesen_US
dc.contributor.authorElhassan, Ahmed M.
dc.contributor.authorElhassana, Adlan M.
dc.contributor.authorPapadogiannakis, Nikos
dc.date2001
dc.date.accessioned2015-11-19T11:21:35Z
dc.date.available2015-11-19T11:21:35Z
dc.date.issued2015-11-19
dc.date.submitted2015
dc.description.abstractThe effects of somatostatin on the development of adjuvant arthritis induced by Mycobacterium butyricum were studied. Somatostatin was injected into the lateral cerebral ventricle every day for 14 days beginning on the first day of mycobacteria inoculation in the preventive group. In the treatment group, somatostatin was injected from day 17 until day 30 post-mycobacteria inoculation. Arthritis was evaluated by measuring ankle joint circumference and diameter as well as microscopic examination of ankle joint sections. Somatostatin profoundly inhibited the development of adjuvant arthritis and an anti-inflammatory action was observed in the treatment group. These results suggest that somatostatin has a central action that can prevent or attenuate symptoms associated with arthritis.en_US
dc.identifier.urihttp://khartoumspace.uofk.edu/123456789/17256
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectSomatostatinen_US
dc.subjectAdjuvanten_US
dc.subjectArthritisen_US
dc.subjectSynoviumen_US
dc.titleIntracerebroventricular administration of somatostatin prevents and attenuates adjuvant arthritisen_US
dc.typePublicationen_US

Files

Collections

Medical and Health
Load more